Orexo Past Earnings Performance
Past criteria checks 0/6
Orexo's earnings have been declining at an average annual rate of -54.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 7.7% per year.
Key information
-54.5%
Earnings growth rate
-54.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -7.7% |
| Return on equity | -217.8% |
| Net Margin | -20.1% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Orexo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 639 | -128 | 306 | 303 |
| 30 Sep 23 | 629 | -201 | 327 | 326 |
| 30 Jun 23 | 634 | -195 | 347 | 319 |
| 31 Mar 23 | 624 | -218 | 362 | 325 |
| 31 Dec 22 | 624 | -178 | 325 | 318 |
| 30 Sep 22 | 612 | -152 | 330 | 310 |
| 30 Jun 22 | 597 | -177 | 348 | 297 |
| 31 Mar 22 | 592 | -216 | 350 | 289 |
| 31 Dec 21 | 565 | -223 | 372 | 272 |
| 30 Sep 21 | 580 | -207 | 374 | 251 |
| 30 Jun 21 | 585 | -240 | 409 | 238 |
| 31 Mar 21 | 621 | -198 | 408 | 228 |
| 31 Dec 20 | 664 | -84 | 389 | 225 |
| 30 Sep 20 | 743 | 4 | 368 | 225 |
| 30 Jun 20 | 824 | 201 | 322 | 216 |
| 31 Mar 20 | 846 | 288 | 341 | 197 |
| 31 Dec 19 | 845 | 219 | 332 | 181 |
| 30 Sep 19 | 834 | 232 | 413 | 170 |
| 30 Jun 19 | 819 | 182 | 421 | 166 |
| 31 Mar 19 | 818 | 178 | 364 | 159 |
| 31 Dec 18 | 783 | 138 | 358 | 167 |
| 30 Sep 18 | 747 | 113 | 275 | 156 |
| 30 Jun 18 | 697 | 79 | 268 | 147 |
| 31 Mar 18 | 656 | 32 | 274 | 149 |
| 31 Dec 17 | 644 | 23 | 287 | 134 |
| 30 Sep 17 | 637 | 19 | 230 | 133 |
| 30 Jun 17 | 653 | 27 | 256 | 128 |
| 31 Mar 17 | 682 | 29 | 303 | 118 |
| 31 Dec 16 | 706 | 29 | 324 | 132 |
| 30 Sep 16 | 752 | -57 | 419 | 154 |
| 30 Jun 16 | 710 | -139 | 434 | 173 |
| 31 Mar 16 | 648 | -229 | 430 | 183 |
| 31 Dec 15 | 646 | -210 | 439 | 173 |
| 30 Sep 15 | 636 | -95 | 412 | 164 |
| 30 Jun 15 | 627 | -85 | 389 | 173 |
| 31 Mar 15 | 617 | -51 | 357 | 185 |
| 31 Dec 14 | 570 | -57 | 307 | 198 |
| 30 Sep 14 | 449 | -146 | 299 | 197 |
| 30 Jun 14 | 440 | -138 | 288 | 208 |
| 31 Mar 14 | 391 | -204 | 252 | 239 |
| 31 Dec 13 | 429 | -155 | 251 | 238 |
| 30 Sep 13 | 413 | -139 | 210 | 241 |
| 30 Jun 13 | 369 | -141 | 181 | 235 |
Quality Earnings: C5G is currently unprofitable.
Growing Profit Margin: C5G is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: C5G is unprofitable, and losses have increased over the past 5 years at a rate of 54.5% per year.
Accelerating Growth: Unable to compare C5G's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: C5G is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: C5G has a negative Return on Equity (-217.83%), as it is currently unprofitable.